Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL
20 Jun 2024 //
PR NEWSWIRE
Dizal`s Golidocitinib Trial Demonstrates Durable Benefits for r/r PTCL
10 Dec 2023 //
PR NEWSWIRE
Golidocitinib Granted Priority Review by NMPA for the Treatment of r/r PTCL
21 Sep 2023 //
PR NEWSWIRE
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib
14 Sep 2023 //
PR NEWSWIRE